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Question under study: The aim of this study
was to determine the prevalence of microalbu-
minuria (MAU) in hypertensive patients attend-
ing an office or hospital based cardiologist or
internist. An additional aim was to describe asso-
ciations between MAU and cardiovascular risk
factors as well as to investigate the role of phar-
macotherapy.
Methods: International, observational, cross-
sectional study of 22282 patients with 5605
attendees in Germany and Switzerland at 444 car-
diology centers. Inclusion criteria were male and
female outpatients, aged ≥18 years with currently
treated or newly diagnosed hypertension
(≥140/90 mm Hg at rest on the day of the study
visit) and no reasons for false positive dip stick
tests. The main outcome measures were the
prevalence of MAU, co-morbid cardiovascular
risk factors or disease and their association with
the presence of MAU, and the role of pharma-
cotherapy in modulating prevalence of MAU.
Results: Prevalence of MAU in Germany and
Switzerland (53.1%) was high, but lower when
compared to the prevalence in “other countries”
(OC, 60.2%). Routine MAU measurement was
performed in 52.9% of the practices only (32.9%
OC), although physicians regarded MAU to be
important for risk assessment and therapeutic de-
cisions. MAU is highly correlated with a wide va-
riety of cardiovascular risk factors and co-morbid
cardiovascular conditions including high waist
circumference (55.1% [95%CI 56.0; 59.7]), dia-
betes (59.1% [56.8; 61.3]), atrial fibrillation
(62.3% [57.4; 66.9]) and peripheral arterial dis-
ease (67.1% [61.6; 72.2]). Angiotensin receptor
blockers (ARBs) appeared to be associated with
the lowest risk of MAU (52.1%). Calcium channel
blockers (CCBs) were used more frequent in pa-
tients with MAU (28.7%) than without (23.4%).
Conclusions: Patients with MAU are common
in clinical cardiology and its presence is associated
with a wide variety of cardiovascular risk factors
and co-morbid cardiovascular conditions. A more
aggressive multi-factorial treatment might help to
reduce this risk constellation.
Key words: microalbuminuria; prevalence; cardi-
ology; hypertension; irbesartan; risk factors
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Introduction
The transgression of albumin into the urine
demarcates a disturbance in the barrier function
of endothelial glomerular cells (podocytes) [1, 2].
A common measurement category is mg/24 h and
albuminuria is frequently standardised for the uri-
nary volume using simultaneous determination of
urinary creatinine.While every excretion of albu-
min into the urine has to be regarded as patho-
logic, a range has been identified at which a pro-
gression to advanced renal disease becomes likely
(30 and 300 mg/24 h). The threshold was termed
microalbuminuria (MAU) and is correlated with
an increased incidence of clinical proteinuria, an
increase in serum creatinine, the more frequent
development of terminal renal insufficiency, but
also associated with an increased cardiovascular
risk [3].
The transgression of albumin into the urine is
frequently regarded as a kidney problem. How-
ever, there is often a simultaneous transgression
of albumin into the retinal bed (cotton wool spots)
[4].Moreover, preclinical studies have shown that,
using labelled albumin, transgression seems to be
also present in the whole vascular system, includ-
ing the myocardium [5]. Consequently, albumin-
uria reflects a generalised endothelial disturbance
and is frequently seen within the context of en-
dothelial dysfunction. Interestingly, an improve-
ment in endothelial function is reflected in a de-
crease of albuminuria [6].
Also for cardiologists, albuminuria seems to
be of critical importance to determine the prog-
nosis of patients with cardiovascular disease. Pa-
tients with myocardial infarction, for example,
have a worse prognosis if albuminuria is present
compared to patients without albuminuria [7].
Furthermore, for patients with angiographically
normal coronary arteries, the extent of endothelial
dysfunction has been shown to correlate to the ex-
tent of albumin excretion [8]. Consequently the
prognosis of patients with CAD and MAU is
worse when compared to patients without [9, 10].
Overall it has been shown that MAU seems to be
more relevant than many established cardiovascu-
lar risk factors [11]. A recent multivariate analysis
of the HOPE trial has shown that the probability
of stroke, myocardial infarction and cardiovascu-
lar death was higher for patients with MAU as
compared to those with PAD, diabetes or the im-
pact of male gender. The analyses further support
the notion that, for cardiovascular risk assessment,
not only MAU but albumin excretion below the
threshold (low grade albuminuria) is already re-
flected in a higher probability of cardiovascular
disease (for a recent review see [12]).
Although there is sound evidence for the im-
portance of MAU in clinical cardiology, there are
no epidemiological data documenting the preva-
lence of this risk marker in clinical cardiology set-
tings and its association with other cardiovascular
risk factors and disease. Therefore the “Interna-
tional Survey Evaluating microAlbuminuria Rou-
tinely by Cardiologists in patients with Hyperten-
sion” (i-SEARCH) was undertaken to answer the
following questions: 1) Prevalence of MAU and its
importance for therapeutic decisions. 2) Associa-
tions with established cardiovascular risk markers
and disease. 3) Relation between coronary artery
disease andMAU. 4) Subsumption of national data
into a global context aiming to compare cardiovas-
cular risk and quality of care with other countries.
The present manuscript therefore reports the data
for Germany and Switzerland, from global data
which have been recently published [13, 14].
Methods
Two step epidemiological design
The current investigation was an international, ob-
servational, cross-sectional study in which participants
were evaluated during a single clinic visit to office and
hospital based cardiologists (methods have been pub-
Abbreviations
ARB angiotensin receptor blocker
CAD coronary artery disease
CABG coronary artery bypass graft
CCB calcium channel blocker
MAU microalbuminuria
PAD peripheral arterial disease
PTCA percutaneous transluminal coronary angiography
RAS renin angiotensin system
lished previously [13]). To allow extrapolation of results
to the broadest possible population, the physician selec-
tion procedure in each country took account of geo-
graphical (west/east, south/north, urban/suburban/rural)
and physician (office/hospital) profiles. In a first step,
prior to patient recruitment, participating physicians
completed a site questionnaire that documented practice
location (urban, suburban or rural) and type (community
or hospital-based), as well as duration of service, and de-
gree of awareness and experience of MAU detection and
its clinical relevance. In a second step at each site, consec-
utive patients fulfilling eligibility criteria (10, max. 15 per
physician) were invited to participate in the study. Insti-
tutional and ethical review board approval for the study
was granted for all participating centres, and all patients
gave written informed consent for study participation.
The study was conducted in accordance with the ethical
principles of the current Declaration of Helsinki and was
consistent with the International Conference on Harmo-
nization Good Clinical Practice (ICH GCP).
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Study population
Inclusion criteria were male and female outpatients,
aged 18 years or older, with currently treated or newly di-
agnosed arterial hypertension, defined as a seated sys-
tolic/diastolic blood pressure of ≥140/90 mm Hg at rest
on the day of the study visit. Patients with acute fever
(>38 °C), renal disease (serum creatinine >20 mg/L), con-
comitant urinary tract infection, receiving treatment with
cimetidine, or having undertaken strenuous physical ac-
tivity in the preceding 24 hours, as well as female subjects
who were pregnant or menstruating were ineligible to
participate due to the likely presence of false positive re-
sults for MAU.
Data acquisition
Once enrolled, the following measurements were
carried out on each patient: heart rate, urinary albumin
and creatinine concentration, and waist and hip circum-
ference. To ensure consistency between study sites, all
centres performed dipstick screening for MAU with
sponsor-provided reagent strips (Microalbustix
®
), which
have a sensivity of 82.6% [15]), and followed a standard-
ised sample collection and testing procedure. Demo-
graphic data, cardiovascular history and presence of car-
diovascular risk factors, co-morbidities, symptoms and
signs of cardiovascular disease, and current chronic drug
therapy were documented on the case report form.
Objectives
The primary objective of this study was to define the
prevalence of MAU in hypertensive outpatients attending
a cardiologist (i-SEARCH A) and to compare prevalence
in hypertensive outpatients with or without coronary ar-
tery disease (i-SEARCH B). Secondary objectives were to
establish a correlation between the prevalence of MAU
and known cardiovascular risk factors in the study popu-
lation, and to increase physicians’ awareness for the im-
portance of MAU screening to identify “at risk patients”.
Statistical analyses
In the present analysis Germany and Switzerland
were compared to other countries [OC] which included
Vietnam, Indonesia, Thailand, Morocco, Australia,
Turkey, Mexico, Taiwan, Sweden, Italy, Spain, Greece,
Belgium, Peru, Colombia, Canada and countries from
the Middle East [13]. Population characteristics were
summarised into counts of non-missing data, means, and
standard deviations (SD) together with 95% confidence
intervals (CI) of the mean for quantitative variables, and
count and percentage with 95% CI of the population for
categorical data. Outcomes included prevalence of MAU
with 95% CIs, taking into account the cluster design ef-
fect using the Proc SURVEYMEANS in SAS for cate-
gorical variables. The association between high levels of
MAU and cardiovascular risk factors and co-morbid con-
ditions (for example history of MI, documented CAD, di-
abetes, dyslipidaemia, a lack of physical exercise and a
history of smoking) was studied using multiple logistic
regression models and prevalence rates were displayed
together with 95% confidence intervals. Since the
amount of data missing was low, the data provided is
without respective sensivity analyses. For the calculations
SAS, version 8.2 was used [16].
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Results
Baseline Characteristics
In 444 practices in Germany and Switzerland
5605 patients were screened, from which 80 did
not sign informed consent and 237 did not meet
the pre-specified inclusion and exclusion criteria,
or either coronary artery disease status, albumin
or creatinine was not documented (Primary analy-
sis population: 5288 patients).
Patients were 64.1 [SD 11.3] years old, 52.3%
were male, had a history of hypertension of 9.0 [SD
8.4] years and a mean blood pressure of 152.6 [SD
19.7] / 89.0 [SD 11.7] mmHg on the study day. For
details on the cardiovascular risk profile see table 1.
From the study population, 17.6% had evi-
dence of coronary artery disease, 46.8% of which
had a history of myocardial infarction. Only 33.2%
had ever had a revascularisation (55.6% OC) with
most patients receiving PTCA only (63.5%) or
CABG only (31.9%). From the sample, 75.4% of
participants had a history of angina pectoris.
Physicians estimated prevalence
and importance of MAU
Physicians stated that MAU was routinely
measured in about half of the practices in Ger-
many and Switzerland (52.9% [95%CI 47.9; 57.8]
compared to 32.9% [30.4; 35.5] in OC). Most
physicians (25.3%) estimated the frequency of
MAU in hypertensive patients, to lie between 11
and 20% (28.3 % OC, for details see fig. 1).
In contrast, 91.9% of treatment decisions and
97.3% of decisions relating to treatment of blood
pressure were said to be influenced by the pres-
ence of MAU. Furthermore 85.4% of physicians
said that MAU also influenced decisions relating
to achieving glycemic control. The vast majority
(98.7%) of physicians linked the presence of
MAU to a worse patient’s prognosis, while 93.1%
also felt that a diagnosis of MAU was relevant to
improving the management of other cardiovascu-
lar risk factors. These attitudes were highly com-
parable with the colleagues in the OC.
Prevalence of MAU
Within the primary analysis population, only
few patients had impaired renal function and
8.95% [95%CI 8.2; 9.8] had previously identified
MAU (5.98% [95%CI 5.6; 6.4] OC). However,
urine analysis with a one time dipstick test re-
vealed that 53.1% [95%CI 51.1; 55.0] of the study
population had evidence of MAU (60.2% [59.0;
61.4] OC), with prevalence rates higher in men
(57.0%) than women (43.0%).
Cardiovascular risk factors associated with
the presence of MAU
Several cardiovascular risk factors were tested
to determine whether they were associated with
the presence of MAU. Male gender, high waist
circumference, systolic blood pressure ≥180 mm
Hg, pulse pressure ≥80 mmHg, high triglycerides
and diabetes were derived as significantly associ-
ated from multivariate analyses and were signifi-
cantly associated with a higher prevalence of
MAU (table 2). In contrast, patients participating
in regular physical exercise and patients with high
HDL cholesterol had a lower risk of MAU. Fig-
ure 2 aggregates these values and shows the num-
ber of present cardiovascular risk factors com-
pared with the presence of MAU.
Cardiovascular disease associated with the
presence of MAU
It was also tested whether MAU was associ-
ated with the presence of cardiovascular disease.
While the presence of an aortic aneurysm was not
associated with the presence of MAU, positive as-
sociations were found with congestive heart fail-
ure, atrial fibrillation, coronary artery disease, a
history of cerebral pathology and peripheral arte-
rial disease (table 2). Figure 3 aggregates these
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Parameter Germany / Switzerland Other countries
(mean ± SD or %) (n = 5288) (n = 15762)
Demographics Age (years) 64.1 ± 11.3 61.8 ± 11.8
<Gender (male, %) 52.3 52.3
BMI (kg/m
2
) 29.8 ± 6.8 28.5 ± 5.3
Hypertension Duration (years) 9.0 ± 8.4 7.8 ± 7.5
SBP (mm Hg) 152.6 ± 19.7 148.1 ± 20.2
DBP (mm Hg) 89.0 ± 11.7 86.9 ± 11.8
Uncontrolled (≥140/90 mm Hg) 84.7 74.2
Heart Rate / Sinus Rhythm Heart rate (bpm) 72.9 ± 11.5 73.9 ± 11.8
Sinus rhythm yes (%) 94.6 94.9
Behavioural risk factors for CVD Family history MI/CAD (%) 28.7 27.6
Regular physical exercise (%) 39.8 33.3
Current/former smoker (%) 12.6 / 21.5 14.7 / 20.1
Additional risk factors Total cholesterol (mmol/L) 5.5 ± 1.1 5.3 ± 1.1
HDL Chol. (mmol/L) 1.5 ± 0.5 1.3 ± 0.4
LDL Chol. (mmol/L) 3.3 ± 1.0 3.2 ± 1.0
Triglycerides (mmol/L) 1.9 ± 1.1 1.8 ± 1.0
CRP (mg/dL) 1.18 ± 1.04 0.8 ± 0.9
Current diabetic (%) 35.1 25.0
Type 1 / Type 2 diabetes (%) 4.1 / 96.0 5.3 / 94.7
Duration of diabetes (years) 8.2 ± 8.6 7.8 ± 7.2
Serum creatinine (μmol/L) 86.9 ± 22.2 90.9 ± 24.3
Creatinine clearance (mL/min) 93.6 ± 33.9 85.8 ± 33.9
<30 mL/min (%) 0.3 0.8
30–60 mL/min (%) 12.9 21.5
60–80 mL/min (%) 25.2 26.9
80–120 mL/min (%) 43.8 37.0
>120 mL/min (%) 17.8 13.7
Co-morbidities CAD (%) 17.6 24.7
Congestive heart failure (%) 5.6 5.9
Atrial fibrillation (%) 7.8 8.5
History of ischemic stroke (%) 4.1 5.1
History of TIA (%) 2.9 4.0
Peripheral artery disease (%) 5.7 3.7
Carotid endarterectomy (%) 22.5 18.4
Other cardiovascular disease LVH (Sokolow mm) 21.0 ± 9.6 (n = 1609) 25.7 ± 9.7 (n = 6702)
Ejection fraction ≤40% (%) 3.8 5.0
Carotid stenosis (%) 3.8 2.6
Aortic aneurysm (%) 1.2 1.4
SD – standard deviation; CAD – coronary artery disease, LVH – left ventricular hypertrophy, TIA – transitory ischemic attack,
CRP – C-reactive protein, MI – myocardial infarction
Table 1
Cardiovascular risk
profile (Primary
analysis population).
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numbers and displays the number of risk factors
present in a patient in relation to the presence of
MAU.
Pharmacotherapy and prevalence of MAU
Use of antihypertensive pharmacotherapy
was more intense in patients with the presence of
MAU. CCBs (+5.3%), ACE Inhibitors (+3.8%),
thiazide diuretics (+1.8%) and beta-blocker
(+2.7%) were more frequently prescribed in pa-
tients with MAU compared to patients without
(fig. 4). The number of patients showing MAU
when receiving pharmacotherapy was in the order
CCBs > ACE Inhibitors > thiazides diuretics >
beta blockers > ARBs (fig. 5).
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Figure 1
Mean prevalence estimates [95% CI].
Risk factor Prevalence of MAU in pts with risk factor Prevalence of MAU in pts without risk factor
(% [95%CI]) (% [95%CI])
Gender Male Female
57.8% [56.0; 59.7] 47.8% [45.8; 49.7]
Waist circumference High Normal
55.1% [53.5; 56.7] 48.0% [45.5; 50.5]
Systolic blood pressure ≥180 mm Hg 120–130 mm Hg
60.8% [56.7; 78.6] 49.1% [43.4; 54.9]
Pulse pressure ≥80 mm Hg between 50 and 60 mm Hg
58.3% [54.3; 62.2] 50.9% [48.3; 53.4]
Triglycerides High Low
55.5% [53.2; 57.7] 50.7% [48.4; 52.9]
Diabetes Present Absent
59.1% [56.8; 61.3] 50.0% [48.3; 51.7]
Physical exercise None Regular
54.6% [52.9; 56.4] 50.7% [48.6; 52.9]
HDL-Cholesterol Low High
61.9% [58.5; 65.2] 50.5% [48.6; 52.3]
Co-morbid disease
CHF Yes No
60.1% [95%CI 54.4; 65.5] 52.6% [51.2; 54.0]
Atrial Fibrillation Yes No
62.3% [57.4; 66.9] 52.4% [51.0; 53.9]
CAD Yes No
57.9% [54.7; 61.0] 52.0 [50.6; 53.5]
Stroke / TIA Yes No
61.8% [57.9; 65.5] 51.9% [50.5; 54.4]
PAD Yes No
67.1% [61.6; 72.2] 52.4% [51.0; 53.8]
MAU, microalbuminuria; CI, confidence interval; CHF, congestive heart failure; CAD, coronary artery disease;
TIA, transitory ischemic attack; PAD, peripheral arterial disease
Figure 2
Mean prevalence estimates [95% CI]; the risk factors
considered are: no regular exercise, current smoking,
known dyslipidemia, family history of myocardial infarction
or documented CAD and Diabetes.
Table 2
Prevalence of MAU
in patients with and
without respective
risk factors or
co-morbid disease
(identified from
multiple regression
analyses).
The demographic characteristics of the present
sample indicate that high risk patients are common
in a hypertensive population seen by cardiologists.
The population were mostly elderly with a substan-
tial cardiovascular risk factor profile and a consider-
able burden of co-morbidity.Therefore, as MAU is
not only a risk marker for diabetic nephropathy but
also indicates a considerable increase in cardiovas-
cular risk, the investigation of the interdependence
of cardiovascular risk and MAU is of particular
value in this patient population. The present sub-
analysis of the Swiss and German centres of the
global i-SEARCH survey generated the following
key results: 1) Patients in Germany and Switzerland
were highly comparable to the OC patient popula-
tion, except that higher rates of diabetes and uncon-
trolled blood pressure were present in Germany
and Switzerland. 2) The prevalence of MAU in
clinical cardiology (53.1%) exceeds the one found
in most of the previous studies in similar popula-
tions, specifically in primary care, and physicians
regard MAU as a cardiovascular risk marker. 3)
MAU is associated with a number of cardiovascular
risk factors and co-morbidities. 4) CCBs are more
frequently used in MAU positive patients as com-
pared to ARBs.
Microalbuminuria is frequent,
but is underestimated
The prevalence of MAU found in the present
sample of hypertensive patients in a cardiologic
outpatient setting indicates that this cardiovascular
risk marker is very common in clinical cardiology
(53.1%). Furthermore it was higher than found in
studies on unselected persons in the general popu-
lation [17–19] and patients in primary care [20, 21].
The HYDRA study in primary care for example
[20] has documented a prevalence of 21.2% of pa-
tients with hypertension and 37.8% of patients with
both hypertension and diabetes. The global DE-
MAND Study has documented a prevalence of
51.8% in patients of general practitioners in Ger-
many (sub-analysis of [21], unpublished). Explana-
tions for this difference may be as follows: In i-
SEARCH, the study population was older than in
most previous studies. Additionally 35% of the en-
rolled hypertensive patients were diabetic, whereas
in other studies [22–24] diabetic subjects were ex-
cluded. Patients with known MAU were also not
excluded as they were in the DEMAND study [21].
These factors and the cardiovascular high risk pop-
ulation attending a cardiologist, in comparison to
primary care, may account for the observed differ-
ences and the somewhat higher prevalence re-
ported in the present study.
Comparing the German and Swiss results to
the results obtained in the OC prevalence it is ap-
parent, that the OC prevalence of MAU (60.2%) is
higher than reported for Germany (53.1%). Fur-
thermore physicians estimated prevalence and
awareness of MAU as a cardiovascular risk marker
is higher than in other countries. Methodological
differences between countries are unlikely to have
resulted in this discrepancy because the question-
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Figure 3
Mean prevalence
estimates [95% CI];
cardiovascular
disease considered
were: History of
myocardial infarction
(MI) or CABG or
PTCA, history of
ischemic stroke or
carotid endarterec-
tomy or carotid
angioplasty, periph-
eral arterial disease
(PAD).
Figure 4
Use of antihypertensive drug classes in patients with (+) or
without (–) microalbuminuria. Mean prevalence estimates
[95% CI] are provided. ARBs – Angiotensin receptor blockers;
ACE – Angiotensin Converting Enzyme; CCBs – Calcium
Channel Blockers.
Figure 5
Mean prevalence
estimates [95% CI]
of MAU in patients
receiving specific
antihypertensive
drug classes; ARBs –
Angiotensin receptor
blockers; ACE –
Angiotensin Convert-
ing Enzyme; CCBs –
Calcium Channel
Blockers.
Discussion
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naires were standardised and a Microalbustix
®
dip
stick test kit for MAU provided to the participating
physician. Given that this test corrects for urine
volume by urine creatinine determination differ-
ences between countries are more likely related to
differences in co-morbidity, and patient care be-
tween more advance health care systems and those
of “third world” countries. Although the prevalence
is high, the estimated prevalence of MAU, the
knowledge about the true prevalence in their pa-
tient cohort and the use of this marker for day to
day decisions on how to proceed with therapy is
low. This finding has also been documented for
general practitioners (HYDRA) [20]. This finding
reflects an important gap that exists between physi-
cian awareness of the prognostic importance of
MAU and actual screening for MAU in cardiology
practices.
MAU is associated with a considerable
cardiovascular risk and disease
MAU was associated with a number of cardio-
vascular risk factors and disease in the present study.
This observation is in agreement with previous data
from population based studies [17] and primary
care [20]. This indicates that MAU is common in
patients who are referred to a cardiologist and is as-
sociated with a number of other cardiovascular risk
factors. This association has been previously de-
scribed in clinical studies for male gender [25] and
older age [26], diabetes [27], obesity [28], smoking
[29], insulin resistance syndrome [30], left ventricu-
lar hypertrophy (LVH) [31], left ventricular dys-
function [32] and CRP [33] (not significant in the
present study). While not all parameters could be
confirmed in the present study, the strong associa-
tion of MAU with a variety of cardiovascular risk
markers is evident.
Interestingly the prevalence of MAU was par-
ticularly low in patients participating in more than
four hours per week of regular exercise or having
high HDL cholesterol. The former finding, which
has been also confirmed in the overall i-SEARCH-
population, is in line with a previous report that
showed MAU is low in physically active patients
and can even be reversed when patients are moti-
vated to perform regular exercise [34].
Therapeutic implications
A wide spectrum of treatments including
statins, ACE inhibitors and ARBs has been shown
to improve endothelial dysfunction,MAU and pro-
teinuria. In the IDNT study [35], for example, the
ARB Irbesartan has been shown to prevent the fur-
ther deterioriation of proteinuria in comparison to
the CCB Amlodipine or standard therapy (beta-
blockers, diuretics, certain CCBs). In the IRMA-2
study it was even shown that an early intervention
results in a reversal and normalisation of albumin
excretion [36]. Therefore it was of particular inter-
est to test whether there are differences between
antihypertensive classes with respect to MAU. The
analyses are difficult to interpret because of un-
known confounding variables and the cross-sec-
tional character of the study but have shown that
CCBs are more widely prescribed in MAU positive
patients than ARBs (which would be reasonable in
combination with RAS blocking agents but usually
not as monotherapy). In contrast, MAU is more
frequently present in patients on CCBs. This may
be a question of what occurred first, MAU or treat-
ment with a CCB, but choice of the substance class
is at least not in agreement with recent study results
discussed previously. Furthermore analyses pre-
sented in the global analysis of the i-SEARCH sur-
vey [13] indicated by using multiple regression
analyses that, while ARBs are at least neutral or
even nominally beneficial in these patients, CCBs
(and beta-blockers) were not. Evidence for favour-
ing ARBs over beta-blockers comes from a sub-
analysis of the LIFE trial. Ibsen and colleagues
compared Atenolol and Losartan with respect to
the cardiovascular outcomes in patients with MAU
and showed that a reduction in MAU was associ-
ated with a significantly reduced risk of non-fatal
myocardial infarction, stroke and cardiovascular
death [37].
MAU is also an established target for primary
prevention, which has been shown in the PRE-
VENT-IT study [38]. Healthy individuals with
MAU, but without hypertension or hypercholes-
terolemia, were treated either with placebo or RAS
blockade. At four-years follow-up, MAU was effec-
tively reduced, which was associated with a 44 %
reduction in cardiovascular events.
Strength and limitations
The main strengths of this cross-sectional
study included a large, referred cohort of hyperten-
sive patients attending a cardiologist or internist,
with validation of predefined primary and second-
ary end points. However, two limitations should be
noted. Firstly, MAU could only be assessed on a
single occasion although guidelines recommend
triple testing (2 out of 3 tests need to be positive).
Therefore the present data may not allow an exact
quantification of how many patients would be posi-
tive or negative on a second occasion. However,
other data suggest that this requirement will only
reduce the point prevalence by one-fifth up [39] to
a maximum of one third [40]. Secondly, a follow up
would allow the closer investigation of the relation
between ARB use and the development or regres-
sion of MAU. This was not done in the present
study but will be part of i-SEARCH Plus, the de-
sign of which has been published recently [41].
Conclusions
Ahigh prevalence ofMAUwas detected in con-
secutive patients attending a cardiology outpatient
setting, indicating that cardiovascular high risk is
common and possibly underestimated. Early detec-
tion, a more aggressive multifactorial treatment to
reduce bloodpressure aswell as to control other car-
diovascular risk factors is warranted to facilitate not
only secondary but also primary prevention.
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